Aspen on the hunt for acquisitions
Emerging markets targeted for growth after disposals slash pharmaceutical giant’s debt
10 September 2020 - 17:33
SA’s biggest pharmaceutical manufacturer Aspen Pharmacare is on the hunt for acquisitions to help it grow its business in emerging markets, after slashing its debt with a series of disposals that concluded this week with Mylan’s acquisition of the commercial rights to its European thrombosis business for €641.9m (R12.7bn).
Aspen CEO Stephen Saad said the company was seeking “bolt-on” rather than transformative acquisitions, and would be looking to buy products to add to its portfolios in the territories it already operated in, which include SA, China, Latin America and Australia...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.